A novel functional polymorphism of GFAP decrease glioblastoma susceptibility through inhibiting the binding of...

Area of Science:

• Neuro-oncology
• Molecular Genetics
• Cancer Biology

Background:

• Glioblastoma (GBM) is a prevalent CNS tumor with unclear genetic underpinnings.
• Glial fibrillary acidic protein (GFAP) is implicated in GBM aggressiveness and poor survival.
• Understanding genetic factors is crucial for improving GBM treatment strategies.

Purpose of the Study:

• To investigate the association between GFAP single nucleotide polymorphisms (SNPs) and GBM chemoresistance and metastasis.
• To elucidate the molecular mechanisms by which GFAP SNPs influence GBM progression.
• To identify potential genetic markers for optimizing GBM clinical trials and personalized therapies.

Main Methods:

• Genotyping of four tagging SNPs in GFAP within a cohort of 667 subjects.
• Bioinformatic analysis of significant SNPs using online tools.
• Functional experiments assessing SNP effects on gene expression, microRNA binding, chemoresistance, and cell migration.

Main Results:

• SNP rs11558961 was significantly associated with GBM susceptibility.
• The rs11558961 variant was predicted to affect miR-139 binding to the GFAP 3'UTR.
• The G-allele of rs11558961 reduced GBM cell chemoresistance and migration, correlating with increased miR-139 responsiveness.

Conclusions:

• The GFAP SNP rs11558961 influences GBM chemoresistance and progression by modulating miR-139 binding.
• This genetic variant may decrease GBM susceptibility through its effects on miR-139.
• Findings offer insights for refining clinical trial designs and personalizing GBM treatment approaches.